Juliane Gassert
Get their honest, personalized take on your startup.
Sign in to pitch Juliane →At a glance
- Full Name
- Juliane Gassert
- Firm
- EMBL Ventures GmbH; also currently listed as Frankfurt support staff at One Equity Partners
- Firm Type
- Venture capital / investment manager
- Investment Stage
- Initial financing through follow-on financing; early development/concept stage through proof of concept
- Target Company Profile
- Entrepreneurial management teams with technical expertise, drive, business sense, a down-to-earth attitude, proprietary core or platform technology, clear competitive advantage, and potential for a leading sustainable market position
- Sector Focus
- Life sciences, therapeutics, target validation, drug design, technology platforms, medical devices, diagnostics
- Geographic Focus
- Europe
- Location
- Heidelberg, Germany for EMBL Ventures; Frankfurt, Germany listing at One Equity Partners
Background
Public information on Juliane Gassert as an individual investment decision-maker is limited. MarketScreener lists Juliane Gassert as connected with EMBL Ventures GmbH, an investment manager focused on disruptive biology and life-science technologies. A separate 2026 One Equity Partners team page lists a Juliane Gassert under Frankfurt support staff, but does not provide a biography or investment role.
A German coaching article describes Juliane Gassert as the “right hand” to managing directors of a venture-capital company before she shifted more attention toward wine writing and events. The same account says she had previously run restaurants in Berlin and Mallorca and later created the wine blog einfachwein.net.
Book-retailer biographical pages for her 2021 book *Leben zwischen Gast und Küche* describe her as born in 1966, trained as a restaurant specialist, and a state-certified sommelier. They state that she spent 25 years in gastronomy, including work as a waitress, restaurant manager, sommelier, involvement in five openings, and consulting on two restaurant concepts.
Investment Thesis & Focus
- EMBL Ventures invests in life-science companies across Europe, particularly new therapeutic treatment modalities, pharmaceuticals, next-generation enabling technology platforms, diagnostics, and medical devices.
- The firm’s stated approach is hands-on and long-term, investing in disruptive biology and life-science-related products and technologies with global potential.
- MarketScreener’s EMBL Ventures profile says the firm seeks teams with “relevant technical expertise, drive, business sense and a down-to-earth attitude,” plus proprietary technology and a clear competitive advantage.
- EMBL Ventures typically acts as lead or co-lead investor in initial financings and participates in follow-on rounds; it targets value inflection points from early development or concept stage to proof of concept.
- No public source found a personal investment thesis, check size, or independently attributed deals for Juliane Gassert.
Notable Investments
- Topas Therapeutics — Clinical-stage biotech developing antigen-specific immune tolerance therapies; EMBL Ventures reported Topas’s Series B financing in 2020 and extension to €40 million in 2021.
- Allecra Therapeutics — Biopharmaceutical company developing antibiotics for multidrug-resistant bacterial infections; Allecra lists EMBL Ventures among its investors, and EMBL Ventures reported U.S. FDA approval for EXBLIFEP in February 2024.
- Crescendo Biologics — Oncology-focused biologics company; EMBL Ventures reported its $70 million Series B financing in April 2018 and BioNTech collaboration in January 2022.
- Immatics — Cancer immunotherapy company; EMBL Ventures reported its 2020 business combination and Nasdaq listing.
- ViraTherapeutics — Oncolytic-virus therapeutics company; EMBL Ventures reported its acquisition by Boehringer Ingelheim in September 2018 for €210 million.
- Luxendo — EMBL spin-off developing light-sheet microscopy systems; funded by the EMBL Technology Fund managed by EMBL Ventures and acquired by Bruker in May 2017.
- Arsanis — Anti-infectives company; EMBL Ventures reported its $45.5 million Series D in April 2017 and IPO closing in November 2017.
- Apellis Pharmaceuticals — Complement therapeutics company; EMBL Ventures reported its IPO closing in November 2017.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.